
|Videos|July 14, 2021
The Use of Clinical Endpoints in the ZUMA-3 Trial
Author(s)Eunice Wang, MD, Bijal D. Shah, MD
Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.
Advertisement
This content originally appeared on our sister site,
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CGTlive®
1
CGTLive®’s Weekly Rewind – January 23, 2026
2
Jeffrey Goldberg, MD, PhD, on the Potential of Cell and Gene Therapy in Glaucoma
3
Around the Helix: Cell and Gene Therapy Company Updates – January 21, 2026
4
Ocugen Posts Positive Preliminary Phase 2 ArMaDa Trial Data of OCU410
5














